Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tailored Approaches to Improve Medication Adherence

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by New York University School of Medicine
Sponsor:
Collaborator:
American Heart Association
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT01643473
First received: July 16, 2012
Last updated: June 23, 2016
Last verified: June 2016

July 16, 2012
June 23, 2016
April 2013
July 2017   (final data collection date for primary outcome measure)
Medication adherence [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Medication adherence will be assessed with an electronic monitoring device (EMD). Adherence is defined as the scheduling adherence metric, which is the proportion of days in which a patient takes their medication correctly divided by the total number of days that s/he is expected to take them in that period.
Same as current
Complete list of historical versions of study NCT01643473 on ClinicalTrials.gov Archive Site
Blood pressure [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Within-patient change in blood pressure is the difference between the baseline and systolic and diastolic BP readings at 6 months
Same as current
Not Provided
Not Provided
 
Tailored Approaches to Improve Medication Adherence
Tailored Approaches to Improve Medication Adherence
The purpose of this study is to to culturally tailor a technology-based individualized adherence intervention for Black and Latino patients with uncontrolled HTN or T2DM, who are non-adherent to their medications, and determine its acceptability.
Using a randomized controlled trial design, this study will compare the efficacy of a tailored adherence intervention (TAI) to a single patient education (PE) session, on medication adherence among 40 high-risk Latino patients with uncontrolled hypertension (HTN) who are non-adherent to their prescribed antihypertensive medications. Patients randomized to the PE group will receive a single patient education session on HTN and medication management by a trained research assistant (RA) at the baseline visit. Patients randomized to the TAI group will complete a tailoring survey at the baseline visit to identify the most salient adherence barriers to the individual, which will be used to create an individualized adherence profile. Following completion of the tailoring survey, patients will collaborate with the RA to identify the most suitable mix of intervention strategies for improving medication adherence (i.e., reminder aids, motivational interviewing, case management) that are matched to the barriers outlined on patients' individualized adherence profiles.
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Hypertension
Behavioral: Adherence Intervention
Patients randomized to the AI group will participate in 9 sessions with bilingual Health Coaches who will utilize a culturally tailored adherence checklist to identify patient's specific medication adherence barriers. Based on the patient's responses, the Health Coach will then engage in targeted patient-centered counseling to assist patients in developing individualized self-monitoring strategies to overcome these barriers and improve adherence behaviors.
  • No Intervention: Usual Care
    Standard care as provided by primary care physician.
  • Experimental: Adherence Intervention
    9 adherence counseling sessions with a health coach
    Intervention: Behavioral: Adherence Intervention
Schoenthaler A, De La Calle F, Barrios-Barrios M, Garcia A, Pitaro M, Lum A, Rosal M. A practice-based randomized controlled trial to improve medication adherence among Latinos with hypertension: study protocol for a randomized controlled trial. Trials. 2015 Jul 2;16:290. doi: 10.1186/s13063-015-0815-x.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
40
September 2017
July 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Have uncontrolled hypertension defined as BP>140/90 mmHg on at least two consecutive visits in the past year (or BP>130/80 mmHg for those with diabetes or kidney disease) and Framingham Risk Scores (FRS) >20% (or at least one CVD risk factor including hyperlipidemia or diabetes);
  • Have been prescribed at least one antihypertensive or oral anti-diabetic medication;
  • Self-identify as Latino or African American/Black
  • Be > 18 years of age

Exclusion Criteria:

  • Refuse or are unable to provide informed consent;
  • Currently participate in another hypertension study; or 2 diabetes study
  • Have significant psychiatric comorbidity
  • Plan to discontinue care at the clinic within the next 3 months

Vulnerable populations including adults unable to provide informed consent, pregnant women, and prisoners will be excluded from this study.

Both
18 Years and older   (Adult, Senior)
No
Contact: Antoinette Schoenthaler, EdD 212-263-4205 antoinette.schoenthaler@nyumc.org
United States
 
NCT01643473
s14-00414
Yes
Not Provided
Not Provided
New York University School of Medicine
New York University School of Medicine
American Heart Association
Principal Investigator: Antoinette Schoenthaler, EdD New York University School of Medicine
New York University School of Medicine
June 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP